Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artículo científico |
| Sprache: | en |
| Veröffentlicht: |
Instituto Nacional de Salud
2019
|
| Schlagworte: | |
| Online-Zugang: | https://www.redalyc.org/articulo.oa?id=84361124008 https://www.redalyc.org/journal/843/84361124008/ https://www.redalyc.org/journal/843/84361124008/html/ https://www.redalyc.org/journal/843/84361124008/84361124008.epub https://www.redalyc.org/journal/843/84361124008/movil |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Inhaltsangabe:
- Coumarin analogue 3-methyl-7H-furo3,2-gchromen-7-one as a possible antiparkinsonian agent María del Pilar Olaya Nadezdha Esperanza Vergel José Luis López María Dolores Viña Mario Francisco Guerrero Medicina models animal levodopa coumarins reserpine Introduction Parkinson’s disease is the second most common neurodegenerative disease. Monoamine oxidase B inhibitors are used in the treatment of this disease concomitantly with levodopa or as monotherapy. Several substituted coumarins have shown activity as inhibitors of monoamine oxidase B.Objective To evaluate the possible antiparkinsonian effects of the coumarin analogue FCS005 (3-methyl-7H-furo3,2-gchromen-7-one) in mouse models, as well as its inhibitory activity towards monoamine oxidases (MAO) and its antioxidant activity.Materials and methods FCS005 was synthesized and the reversal of hypokinesia was evaluated in the reserpine and levodopa models. Moreover, in the haloperidol model, its anticataleptic effects were evaluated. Additionally, the monoamine oxidase inhibitory activity and antioxidant activity of FCS005 were evaluated using in vitro and ex vivo studies, respectively.Results FCS005 (100 mg/kg) caused the reversal of hypokinesia in the reserpine and levodopa models. This furocoumarin also presented anti-cataleptic effects at the same dose. Besides, it showed selective inhibitory activity towards the MAO-B isoform and antioxidant activity. Conclusion These results attribute interesting properties to the compound FCS005. It is important to continue research on this molecule considering that it could be a potential antiparkinsonian agent. 2019 artículo científico 0120-4157 https://www.redalyc.org/articulo.oa?id=84361124008 https://www.redalyc.org/journal/843/84361124008/ https://www.redalyc.org/journal/843/84361124008/html/ https://www.redalyc.org/journal/843/84361124008/84361124008.epub https://www.redalyc.org/journal/843/84361124008/movil 10.7705/biomedica.4299 en http://www.redalyc.org/revista.oa?id=843 Biomédica application/pdf Instituto Nacional de Salud Biomédica (Colombia) Num.3 Vol.39